Vertebral fractures in males with type 2 diabetes treated with rosiglitazone

Bone

Volumn 45, Issue 4, 2009, Pages 784-788

  Mancini, Tatiana ^a   Mazziotti, Gherardo ^b,c   Doga, Mauro ^b   Carpinteri, Rita ^b   Simetovic, Niksa ^a   Vescovi, Pier Paolo ^c   Giustina, Andrea ^b  

^a San Marino State Hospital   (San Marino)

^b UNIVERSITY OF BRESCIA   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

Author keywords

Morphometry; Osteoporosis; Rosiglitazone; Type 2 diabetes; Vertebral fractures

Indexed keywords

25 HYDROXYVITAMIN D; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PARATHYROID HORMONE; ROSIGLITAZONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MONOTHERAPY; MORPHOMETRICS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL;

AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; SPINAL FRACTURES; THIAZOLIDINEDIONES;

EID: 68849110963     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.06.006     Document Type: Article

References (35)

1. Tuominen J.T., Impivaara O., Puukka P., and Rönnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22 7 (1999) 1196-2000
2. Strotmeyer E.S., Cauley J.A., Schwartz A.V., Nevitt M.C., Resnick H.E., Bauer D.C., et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch. Intern. Med. 165 14 (2005) 1612-1617
3. Lipscombe L.L., Jamal S.A., Booth G.L., and Hawker G.A. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 30 4 (2007) 835-841
4. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos. Int. 18 (2007) 427-444
5. Melton III L.J., Riggs B.L., Leibson C.L., Achenbach S.J., Camp J.J., Bouxsein M.L., et al. A bone structural basis for fracture risk in diabetes. J. Clin. Endocrinol. Metab. 93 (2008) 4804-4809
6. Yamamoto M., Yamaguchi T., Yamauchi M., Kaji H., and Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J. Bone Miner. Res. 24 (2009) 702-709
7. Yaturu S., Bryant B., and Jain S.K. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30 (2007) 1574-1576
8. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos. Int. 19 2 (2008) 129-137
9. Meier C., Kraenzlin M.E., Bodmer M., Jick S.S., Jick H., and Meier C.R. Use of thiazolidinediones and fracture risk. Arch. Intern. Med. 168 8 (2008) 820-825
10. Loke Y.K., Singh S., and Furberg C.D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180 1 (2009) 32-39
11. Kahn S.E., Zinman B., Lachin J.M., Haffner S.M., Herman W.H., Holman R.R., et al., Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31 5 (2008) 845-851
12. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 9493 (2005) 1279-1289
13. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., et al. Tuzcu EM;PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 13 (2008) 1561-1573
14. Seufert J., and Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 79 3 (2008) 453-460
15. Genant H.K., Jergas M., Palermo L., Nevitt M., Valentin R.S., Black D., et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in the osteoporosis. The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11 (1996) 984-996
16. Jalava T., Sarna S., Pylkkänen L., Mawer B., Kanis J.A., Selby P., et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18 (2003) 1254-1260
17. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 29 (2006) S4-42
18. Bonadonna S., Mazziotti G., Nuzzo M., Bianchi A., Fusco A., De Marinis L., et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Miner. Res. 20 (2005) 1837-1844
19. Hanley D.A., Brown J.P., Tenenhouse A., Olszynski W.P., Ioannidis G., Berger C., et al., Canadian Multicentre Osteoporosis Study Research Group. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J. Bone Miner. Res. 18 4 (2003) 784-790
20. Lazarenko O.P., Rzonca S.O., Hogue W.R., Swain F.L., Suva L.J., and Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148 6 (2007) 2669-2680
21. Canalis E., Giustina A., and Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357 (2007) 905-916
22. Lecka-Czernik B., Ackert-Bicknell C., Adamo M.L., Marmolejos V., Churchill G.A., Shockley K.R., et al. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148 2 (2007) 903-911
23. Giustina A., Mazziotti G., and Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29 5 (2008) 535-559
24. Monami M., Cresci B., Colombini A., Pala L., Balzi D., Gori F., et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 31 2 (2008) 199-203
25. Mazziotti G., Angeli A., Bilezikian J.P., Canalis E., and Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17 (2006) 144-149
26. Mazziotti G., Bianchi A., Bonadonna S., Nuzzo M., Cimino V., Fusco A., et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21 (2006) 520-528
27. Mazziotti G., Bianchi A., Bonadonna S., Cimino V., Patelli I., Fusco A., et al. Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93 12 (2008) 4649-4655
28. Khosla S., Amin S., and Orwoll E. Osteoporosis in men. Endocr. Rev. 29 4 (2008) 441-464
29. Carruthers M., Trinick T.R., Jankowska E., and Traish A.M. Are the adverse effects of glitazones linked to induced testosterone deficiency?. Cardiovasc. Diabetol. 15 7 (2008) 30
30. Kapoor D., Channer K.S., and Jones T.H. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab. Vasc. Dis. Res. 5 2 (2008) 135-137
31. Cohen P. Rosiglitazone increases testosterone in hypogonadal type 2 diabetic men. Diab. Vasc. Dis. Res. 6 1 (2009) 51
32. Reid I.R. Relationships between fat and bone. Osteoporos. Int. 19 5 (2008) 595-606
33. Norris S.L., Carson S., and Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Curr. Diabetes Rev. 3 2 (2007) 127-140
34. Bossoni S., Mazziotti G., Gazzaruso C., Martinelli D., Orini S., Solerte S.B., et al. Relationship between instrumental activities of daily living and blood glucose control in elderly subjects with type 2 diabetes. Age Ageing 37 2 (2008) 222-225
35. Mazziotti G., Bossoni S., Orini S., Salimbeni P., Gazzaruso C., Solerte B.S., et al. Treatment with metformin is protective against limitations in instrumental activities of daily living in older subjects with type 2 diabetes mellitus. J. Am. Geriatr. Soc. 57 3 (2009) 562-564